CRISPR Cas9 gRNA Targeting JCV T-Ag Gene
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for progressive multifocal leukoencephalopathy (PML) caused by the John Cunningham virus (JCV) are largely ineffective, and there is a need for new strategies that can target and eliminate JCV from host cells.
Innovation Solution
The use of CRISPR-associated endonucleases, such as Cas9, guided by specific guide RNA (gRNA) sequences complementary to target sequences in the JCV DNA, particularly in the large T antigen (T-Ag) gene, to cleave and eliminate the JCV genome from host cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for PML caused by JCV, then the treatment approach is simple and familiar, but the treatments are largely ineffective and cannot eliminate the virus
Solution Approach 1:
The patent introduces CRISPR-associated endonucleases (Cas9) guided by specific gRNA sequences as intermediary molecules that precisely target and cleave JCV DNA. This mediator system enables effective viral elimination by bridging the gap between conventional ineffective treatments and the need for specific viral genome destruction, resolving the contradiction between treatment simplicity and effectiveness.
Solution Approach 2:
The invention changes the fundamental parameter of treatment mechanism from conventional antiviral approaches to CRISPR-mediated genomic cleavage. By altering the treatment paradigm to use guide RNA sequences complementary to specific JCV target sequences (particularly in the T-Ag gene), the treatment achieves reliable viral elimination while maintaining a relatively straightforward delivery system.
2Reliability
If CRISPR-associated endonucleases are used to target and eliminate JCV, then viral elimination effectiveness is improved, but the risk of off-target effects on healthy genes increases
Solution Approach 1:
The patent applies local quality by designing gRNA sequences with high specificity to target only particular regions of the JCV genome (especially the T-Ag gene). This localized targeting ensures that the CRISPR system acts precisely where needed - on viral DNA sequences - while leaving host genomic DNA unaffected, thereby resolving the contradiction between effective viral elimination and minimizing off-target effects.
Solution Approach 2:
The invention incorporates feedback mechanisms through careful selection and validation of gRNA sequences that maximize specificity to JCV targets. By using multiple gRNAs targeting different regions of the viral genome and validating their specificity, the system provides feedback control that prevents off-target cleavage while maintaining effective viral elimination.
3Reliability
If multiple gRNA sequences are used to target different regions of the JCV genome, then the completeness of viral elimination is improved, but the complexity of the treatment composition increases
Solution Approach 1:
The patent merges multiple gRNA sequences into a single treatment composition that can be delivered together. By combining several gRNAs targeting different regions of the JCV genome (including the T-Ag gene and other essential viral genes) with a single Cas9 endonuclease, the system achieves complete viral elimination through coordinated cleavage at multiple sites, while simplifying the delivery mechanism compared to using separate treatment components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively eliminates JCV from infected host cells and prevents future infections, while minimizing off-target effects on healthy genes.
Implementation Method 1
guided by specific guide RNA (gRNA) sequences complementary to target sequences in the JCV DNA
Implementation Method 2
CRISPR-associated endonucleases, such as Cas9... to cleave and eliminate the JCV genome
Data Source
AI summary
The present invention includes methods and compositions for elimination of polyomaviruses, such as John Cunningham Virus (JVC), from host cells, and the treatment of polyomavirus related diseases, such as progressive multifocal leukoencephalopathy (PML). The compositions include isolated nucleic acid sequences comprising an CRISPR-associated endonuclease and a guide RNA, wherein the guide RNA is complementary to a target sequence in a polyomavirus.